stockrow
Friday 6 November 2026
Export TTOO’s income statement to Excel — free account
T2 Biosystems, Inc.
TTOO Healthcare Diagnostics & Research
T2 Biosystems, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $7.2 million, down 67.8% from fiscal 2022.
0.00
0.00
NaN
Follow TTOO
Alert me
| Sep '24 | Jun '24 | Mar '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | 1 | 2 |
+8 more TTM periods Free account |
| 277.61% | 228.08% | 104.14% | 147.96% | ||
| (140.00%) | (164.01%) | (158.80%) | (144.89%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
326.10% | 662.39% | 116.79% | 170.88% | |
Average Days of Receivables |
96.66 | 66.08 | 80.77 | 72.06 | |
Free Cash Flow per Share |
(2.05) | (3.10) | (9.20) | (18.52) | |
Free Cash Flow |
(36.59) | (43.73) | (46.88) | (48.33) | |
Capital Expenditures |
— | — | — | (0.19) | |
| Other line items | |||||
Cash ROIC |
380.10% | 2,647.28% | 148.52% | 391.41% | |
Accounts Receivable Turnover |
4.84 | 5.42 | 4.93 | 4.02 | |
Accounts Payable Turnover |
5.12 | 6.83 | 6.21 | 10.88 | |
Inventory Turnover |
3.35 | 2.82 | 3.24 | 3.38 | |
Average Days of Payables |
113.24 | 45.95 | 44.24 | 36.28 | |
Days of Inventory on Hand |
102.88 | 140.86 | 109.48 | 114.49 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
168.27% | 180.26% | 186.78% | 196.76% | |
Selling, General and Administrative Expense of Revenue |
297.56% | 327.28% | 338.20% | 345.20% | |
Share Based Compensation of Revenue |
35.78% | 47.57% | 57.32% | 60.49% | |
Interest Coverage |
(13.07) | (11.46) | (9.72) | (9.30) | |
Operating CF/Net income |
0.85 | 0.91 | 1.03 | 0.96 | |
Depreciation/Fixed assets |
0.18 | 0.30 | 0.41 | 0.52 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.22) | |
Revenue per Share |
0.43 | 0.51 | 1.41 | 2.76 | |
Operating CF per Share |
(2.05) | (3.10) | (9.20) | (18.44) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.07) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.03 |
Columns are period end dates · fundamentals updated 26 Oct 2026